Testing chemotherapy effectiveness for olfactory neuroblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the efficacy and safety of different induction chemotherapy regimens in patients diagnosed with olfactory neuroblastoma. Participants will receive either Gemcitabine combined with Cisplatin or a regimen of Cyclophosphamide, Etoposide, and Cisplatin, based on their tumor's molecular profile. The study will assess tumor remission rates and long-term survival outcomes to determine the most effective treatment approach for various pathology subtypes of the disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with pathologically confirmed olfactory neuroblastoma;
2. Age ≥ 18 years old;
3. Dulguerov stage T2-T4;
4. Patients who signed the informed consent forms;
5. No distant metastasis.

Exclusion Criteria:

1. Patients with uncontrolled concurrent diseases that the researchers believe will interfere with treatment;
2. Any situation in which the patient may interfere with the compliance or safety during the study;
3. Severe neurological or mental illness, including dementia and seizures;
4. Uncontrolled active infection;
5. Pregnant or lactating women;
6. Persons without personal freedom and independent capacity for civil conduct;
7. Other situations that are not suitable for joining the group.

Where it's running

• Eye & ENT Hospital of Fudan University
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Hongmeng Yu, Prof. — Eye & ENT Hospital, Fudan University
• Study coordinator: Xiaole Song, MD
• Email: jxfxsxl@163.com
• Phone: 15821388769

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy [212Pb]VMT-Alpha-NET for SSTR-positive metastatic or inoperable GI neuroendocrine, pheochromocytoma/paraganglioma, small cell lung, kidney, and head & neck cancers

  This trial will try an experimental targeted alpha-particle drug called [212Pb]VMT-Alpha-NET in adults whose metastatic or inoperable tumors show somatostatin receptor (SSTR) expression.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06479811

• Understanding the natural history of olfactory neuroblastoma in patients

  This study is trying to learn more about olfactory neuroblastoma, a rare cancer in the nose, by gathering information on how it develops and affects patients to improve treatment options.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT04755205

• Neoadjuvant finotonlimab plus TP chemotherapy for SMARCB1-deficient sinonasal cancer

  This study tests whether giving finotonlimab with the TP chemotherapy regimen before surgery can shrink locally advanced SMARCB1-deficient sinonasal tumors in adults.

  Recruiting Phase 2 Eye & ENT Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT07927465

• Intelligent case management for microtia care from diagnosis through rehabilitation

  This trial tests a mobile, intelligent case-management platform to provide continuous, personalized nursing and health guidance for people with congenital microtia undergoing ear reconstruction.

  Recruiting Eye & ENT Hospital of Fudan University · Shanghai · NCT07846345

• Becotatug Vedotin plus PD-1 inhibitor for locally recurrent nasopharyngeal carcinoma

  This study tests whether adding becotatug vedotin to a PD-1 inhibitor helps people with locally recurrent nasopharyngeal cancer.

  Recruiting Phase 2 Eye & ENT Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT07781358

• Customized bifocal plus defocus lenses to slow myopic shift after congenital cataract surgery

  This study tests whether individually tailored bifocal plus defocus glasses can slow myopic progression in children aged 4–12 who had bilateral congenital cataract surgery.

  Recruiting Eye & ENT Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT07778797

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.